Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health treatment, announced that CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The presentation is scheduled for Monday, Nov. 9, 2026, at 3 p.m. ET. The fireside chat will be webcast live, with registration available through the conference webcast platform. A replay will be available on the Events & Presentations page of the company’s investor relations website. To view the full press release, visit https://ibn.fm/LrRvm.
The conference appearance comes as Helus Pharma advances its pipeline of proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company’s NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health.
Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA, in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and to learn more about Helus Pharma, visit www.helus.com.
The presentation at the Guggenheim Healthcare Innovation Conference is significant for investors and industry observers because it offers a direct update from leadership on Helus Pharma’s clinical progress and strategic outlook. With HLP003 in Phase 3 and holding Breakthrough Therapy Designation, the company is at a critical juncture in its efforts to bring a new class of mental health treatments to market. The fireside chat format allows for a detailed discussion of the company’s approach to developing NSAs, which could potentially reshape treatment paradigms for depression and anxiety if clinical trials succeed.
The announcement was disseminated on behalf of Helus Pharma and may include paid advertising. The full press release is available through Helus Pharma. InvestorWire, a specialized communications platform, distributed the release. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For more information, see the full terms of use and disclaimers on the InvestorWire website.
